ArticleDiagnostic pathology2026
Integrating ANP32A expression with Ann Arbor stage refines prognostic stratification in extranodal NK/T-cell lymphoma.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsTo investigate the expression of acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) in extranodal NK/T-cell lymphoma (ENKTL) and to evaluate its relationship with clinicopathological characteristics, proliferative activity, and prognosis.
methodsA total of 63 patients with ENKTL diagnosed at the First Affiliated Hospital of Zhengzhou University between 2012 and 2021 were retrospectively included. Reactive lymphoid tissue from the nasopharynx was used as the control tissue. Immunohistochemistry was performed to detect ANP32A expression in ENKTL and control tissues. The association between ANP32A expression and clinicopathological characteristics, Ki-67 index, and patient survival was analyzed. Kaplan-Meier survival analysis, univariate and multivariate Cox regression analyses, and receiver operating characteristic (ROC) curve analysis were performed to assess the prognostic significance of ANP32A.
resultsAmong the 63 patients with ENKTL, there were 42 males and 21 females, with a median age of 50 years (range, 12-80 years). Compared with control tissues, ANP32A expression was increased in ENKTL tissues, and positive staining was mainly localized in the nuclei of tumor cells. According to the modified H-score, 23 cases showed high ANP32A expression and 40 cases showed low expression. High ANP32A expression was significantly associated with advanced Ann Arbor stage, higher Prognostic Index for Natural Killer Lymphoma (PINK) score, elevated β2-microglobulin level, and high Ki-67 index (all P < 0.05). Spearman correlation analysis showed a weak positive correlation between ANP32A expression and Ki-67 index (r = 0.330, P < 0.01). Kaplan-Meier analysis showed that patients with high ANP32A expression had significantly shorter overall survival (OS) than those with low expression (log-rank P < 0.0001). Univariate Cox regression analysis showed that high ANP32A expression was associated with poor prognosis (hazard ratio(HR) = 4.55; 95% confidence interval (CI), 2.50-8.52; P < 0.001). Multivariate Cox regression analysis further demonstrated that ANP32A high expression remained an independent adverse prognostic factor (HR = 3.61, 95% CI: 1.95-6.89, P < 0.001). ROC analysis showed that the area under the curve (AUC) of ANP32A alone for predicting OS was 0.776, which was higher than that of Ann Arbor stage alone (AUC = 0.667); when combined with Ann Arbor stage, the AUC increased to 0.800.
conclusionsANP32A is increased in ENKTL and is associated with aggressive clinicopathological features, increased proliferative activity, and poor survival outcome. ANP32A may serve as a useful supplementary prognostic marker in ENKTL and may provide additional prognostic information when combined with Ann Arbor stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.